STOCK TITAN
  1. Home
  2. News
  3. NUMIF

NUMINUS WELLNESS INC - $NUMIF STOCK NEWS

Welcome to our dedicated page for NUMINUS WELLNESS news (Ticker: $NUMIF), a resource for investors and traders seeking the latest updates and insights on NUMINUS WELLNESS stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect NUMINUS WELLNESS's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of NUMINUS WELLNESS's position in the market.

News
Numinus Congratulates MAPS on its Application to the FDA for MDMA-Assisted Therapy for PTSD
Rhea-AI Summary
Numinus Wellness Inc. (NUMI) congratulates MAPS PBC for submitting an NDA to the FDA for MDMA-assisted therapy for PTSD. Numinus expands its Practitioner Training Program and receives a notification from OTC Markets Inc. regarding its OTCQX compliance.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.23%
Tags
none
-
News
Numinus Wellness Inc. Announces Fourth Quarter and Full Year Fiscal 2023 Results
Rhea-AI Summary
Numinus Wellness Inc. (NUMI) Q4 2023 Highlights: Revenues grew 46.8% YoY to $6.1M, gross profit increased 37.4%, cash position at $8.6M, and fiscal 2023 revenue of $23.2M, a 256.9% increase over F2022.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.38%
Tags
earnings
-
News
Numinus to Host Q4 2023 and Annual Results Conference Call on November 29, 2023
Rhea-AI Summary
Numinus Wellness Inc. (NUMI) to Release Financial Results for Q4 and Year-End 2023, Announces Conference Call and Webcast
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4%
Tags
conferences earnings
News
Numinus Announces Psychedelic Program for Mental Distress Associated with Chronic and Serious Illness through Cedar Clinical Research
Rhea-AI Summary
Numinus introduces innovative psychedelic program for mental distress associated with chronic and serious illness
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.98%
Tags
clinical trial
-
News
Numinus Wellness Inc. Announces At-The-Market Offering Equity Program
Rhea-AI Summary
Numinus Wellness Inc. establishes an at-the-market equity offering program, allowing the company to issue and sell up to C$10,000,000 of common shares. The program provides flexibility for future financing and general corporate purposes. No shares have been distributed yet.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.41%
Tags
none
-
News
Numinus Congratulates MAPS on its Phase 3 Study Results Published in Nature Medicine
Rhea-AI Summary
Numinus congratulates MAPS on its phase 3 study results published in Nature Medicine
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.48%
Tags
clinical trial
News
Numinus Takes Actions to Accelerate its Path to Profitability by Focusing on Positive Cash Flow Generating Operations
Rhea-AI Summary
Numinus Wellness Inc. is ceasing operations at its non-revenue producing research lab and consolidating clinic operations to improve performance and client experience. These actions are expected to save nearly C$1 million in annual cash expenses, improving company margins and supporting profitability. The company will retain all intellectual property and licenses. Clinic locations are being consolidated and leases for research clinics in Montreal and Vancouver will not be renewed. These changes are expected to enhance service levels and client experience. Overall, these actions are expected to reduce annual cash expenses by C$1 million without significant impact on revenue. Numinus believes these actions will improve margins and accelerate its path to positive cash flow and profitability.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.48%
Tags
none
-
News
Numinus to Participate in a Water Tower Research Fireside Chat on Thursday, August 17, 2023
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.38%
Tags
conferences
-
News
Numinus Wellness Inc. Reports Q3 2023 Results
Rhea-AI Summary
Numinus Wellness Inc. announced its Q3 2023 financial results. Revenues grew 713.3% YoY to $6.0 million and 12.6% from the previous quarter. Gross profit was $2.1 million, a 1051.6% YoY increase. The company incurred $0.6 million of one-time expenses due to staff reductions. Cash position was $13.0 million as of May 31, 2023. Activities during Q3 position the company well for the expected future approval of MDMA-assisted therapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.65%
Tags
earnings
News
Numinus to Present at the Small Cap Growth Virtual Investor Conference on July 13, 2023
Rhea-AI Summary
Numinus Wellness Inc. to present at Small Cap Growth Virtual Investor Conference on July 13, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.56%
Tags
conferences
Stock NUMIF logo
NUMINUS WELLNESS INC

OTC:NUMIF

NUMIF Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

NUMIF Stock Data

23.62M
258.18M
3.9%
2.73%
Testing Laboratories
Professional, Scientific, and Technical Services
Link
United States of America
Vancouver